Literature DB >> 20935067

Antisense tools for functional studies of human Argonaute proteins.

Alessandra Mescalchin1, Anke Detzer, Ulrike Weirauch, Maximilian J Hahnel, Christina Engel, Georg Sczakiel.   

Abstract

The Argonaute proteins play essential roles in development and cellular metabolism in many organisms, including plants, flies, worms, and mammals. Whereas in organisms such as Caenorhabditis elegans and Arabidopsis thaliana, creation of Argonaute mutant strains allowed the study of their biological functions, in mammals the application of this approach is limited by its difficulty and in the specific case of Ago2 gene, by the lethality of such mutation. Hence, in human cells, functional studies of Ago proteins relied on phenotypic suppression using small interfering RNA (siRNA) which involves Ago proteins and the RNA interference mechanism. This bears the danger of undesired or unknown interference effects which may lead to misleading results. Thus, alternative methods acting by different regulatory mechanisms would be advantageous in order to exclude unspecific effects. The knockdown may be achieved by using specific antisense oligonucleotides (asONs) which act via an RNase H-dependent mechanism, not thought to interfere with processes in which Agos are involved. Different functional observations in the use of siRNA versus asONs indicate the relevance of this assumption. We developed asONs specific for the four human Agos (hAgos) and compared their activities with those obtained by siRNA. We confirm that hAgo2 is involved in microRNA (miRNA)- and in siRNA-mediated silencing pathways, while the other hAgos play a role only in miRNA-based gene regulation. Using combinations of asONs we found that the simultaneous down-regulation of hAgo1, hAgo2, and hAgo4 led to the strongest decrease in miRNA activity, indicating a main role of these proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935067      PMCID: PMC2995413          DOI: 10.1261/rna.2204610

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  55 in total

1.  Concepts to automate the theoretical design of effective antisense oligonucleotides.

Authors:  R K Far; W Nedbal; G Sczakiel
Journal:  Bioinformatics       Date:  2001-11       Impact factor: 6.937

Review 2.  Antisense oligonucleotides: basic concepts and mechanisms.

Authors:  Nathalie Dias; C A Stein
Journal:  Mol Cancer Ther       Date:  2002-03       Impact factor: 6.261

3.  Characterization of endogenous human Argonautes and their miRNA partners in RNA silencing.

Authors:  Asuka Azuma-Mukai; Hideo Oguri; Toutai Mituyama; Zhi Rong Qian; Kiyoshi Asai; Haruhiko Siomi; Mikiko C Siomi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-04       Impact factor: 11.205

4.  A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability.

Authors:  V Patzel; U Steidl; R Kronenwett; R Haas; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

5.  MicroRNA-directed transcriptional gene silencing in mammalian cells.

Authors:  Daniel H Kim; Pål Saetrom; Ola Snøve; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

6.  Prolyl 4-hydroxylation regulates Argonaute 2 stability.

Authors:  Hank H Qi; Pat P Ongusaha; Johanna Myllyharju; Dongmei Cheng; Outi Pakkanen; Yujiang Shi; Sam W Lee; Junmin Peng; Yang Shi
Journal:  Nature       Date:  2008-08-06       Impact factor: 49.962

Review 7.  Antisense technologies. Improvement through novel chemical modifications.

Authors:  Jens Kurreck
Journal:  Eur J Biochem       Date:  2003-04

8.  Importance of translation and nonnucleolytic ago proteins for on-target RNA interference.

Authors:  Ligang Wu; Jihua Fan; Joel G Belasco
Journal:  Curr Biol       Date:  2008-09-09       Impact factor: 10.834

9.  Structure of the guide-strand-containing argonaute silencing complex.

Authors:  Yanli Wang; Gang Sheng; Stefan Juranek; Thomas Tuschl; Dinshaw J Patel
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

10.  Maternal Argonaute 2 is essential for early mouse development at the maternal-zygotic transition.

Authors:  Karin Lykke-Andersen; Michael J Gilchrist; Joanna B Grabarek; Partha Das; Eric Miska; Magdalena Zernicka-Goetz
Journal:  Mol Biol Cell       Date:  2008-08-13       Impact factor: 4.138

View more
  7 in total

Review 1.  Demystifying the nuclear function of Argonaute proteins.

Authors:  Vera Huang; Long-Cheng Li
Journal:  RNA Biol       Date:  2014-01-02       Impact factor: 4.652

Review 2.  miRNA goes nuclear.

Authors:  Vera Huang; Long-Cheng Li
Journal:  RNA Biol       Date:  2012-03-01       Impact factor: 4.652

3.  Cell stress is related to re-localization of Argonaute 2 and to decreased RNA interference in human cells.

Authors:  Anke Detzer; Christina Engel; Winfried Wünsche; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2010-12-08       Impact factor: 16.971

4.  Upregulation of Cyclin B1 by miRNA and its implications in cancer.

Authors:  Vera Huang; Robert F Place; Victoria Portnoy; Ji Wang; Zhongxia Qi; Zhejun Jia; Angela Yu; Marc Shuman; Jingwei Yu; Long-Cheng Li
Journal:  Nucleic Acids Res       Date:  2011-11-03       Impact factor: 16.971

5.  Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells.

Authors:  Vera Huang; Jiashun Zheng; Zhongxia Qi; Ji Wang; Robert F Place; Jingwei Yu; Hao Li; Long-Cheng Li
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

Review 6.  Biogenesis and mechanism of action of small non-coding RNAs: insights from the point of view of structural biology.

Authors:  Marina C Costa; Ana Lúcia Leitão; Francisco J Enguita
Journal:  Int J Mol Sci       Date:  2012-08-17       Impact factor: 6.208

7.  The roles of individual mammalian argonautes in RNA interference in vivo.

Authors:  Vera M Ruda; Rohit Chandwani; Alfica Sehgal; Roman L Bogorad; Akin Akinc; Klaus Charisse; Alexander Tarakhovsky; Tatiana I Novobrantseva; Victor Koteliansky
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.